APA (7th ed.) Citation

Xuanhong Jin, Yang Pan, Cheng Cheng, Hangchen Shen, Chongya Zhai, Kailai Yin, . . . Liangkun You. (2024). Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: The impact of antiangiogenic agents. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Xuanhong Jin, Yang Pan, Cheng Cheng, Hangchen Shen, Chongya Zhai, Kailai Yin, Xinyu Zhu, Hongming Pan, and Liangkun You. Optimizing First-line TKI Treatment Efficacy in PD-L1-positive EGFR-mutated NSCLC: The Impact of Antiangiogenic Agents. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Xuanhong Jin, et al. Optimizing First-line TKI Treatment Efficacy in PD-L1-positive EGFR-mutated NSCLC: The Impact of Antiangiogenic Agents. Frontiers Media S.A., 2024.